تداخلات فيتامين ك

Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (نشرة بوتالبيتال وأسبرين وكافيين، موانع الاستعمال)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (نشرة ريفامبيسين، التحذيرات)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (نشرة فوسفينيتوين، التحذيرات والاحتياطات)

Do not administer agents that enhance the risk of hemorrhage with fondaparinux sodium unless essential for the management of the underlying condition, such as vitamin K antagonists for the treatment of VTE. (نشرة فوندابارينوكس، التحذيرات والاحتياطات)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (نشرة فينيتوين، التحذيرات والاحتياطات)

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (نشرة كابيسيتابين، تحذير مؤطر)

فيتامين ك يقلّل الأثر المضاد للتخثر لوارفارين؛ والتغيّرات المفاجئة في المتناول منه من المكملات أو النظام الغذائي قد تخلّ بقيمة INR. (NIH Office of Dietary Supplements, Vitamin K)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (نشرة أبيكسابان، التحذيرات والاحتياطات)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (نشرة أورليستات، التداخلات الدوائية)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (نشرة إيدوكسابان، التحذيرات والاحتياطات)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (نشرة بروبيل ثيوراسيل، التداخلات الدوائية)

Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (نشرة بنتوكسيفيلين، التداخلات الدوائية)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (نشرة بيكالوتاميد، التحذيرات والاحتياطات)

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (نشرة دابيغاتران، التحذيرات والاحتياطات)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (نشرة ريفاروكسابان، التحذيرات والاحتياطات)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (نشرة سوغاماديكس، التحذيرات والاحتياطات)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (نشرة سيفازولين، التحذيرات والاحتياطات)

Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (نشرة سيفترياكسون، التحذيرات والاحتياطات)

Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (نشرة سيفوتيتان، التحذيرات)

Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (نشرة سيفيبيم، التحذيرات والاحتياطات)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (نشرة سيفيكسيم، التحذيرات والاحتياطات)

Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (نشرة كوليسيفيلام، التحذيرات والاحتياطات)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (نشرة كينين، التداخلات الدوائية)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (نشرة ليفوثيروكسين وليوثيرونين، التداخلات الدوائية)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (نشرة ميثيمازول، التداخلات الدوائية)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (نشرة نيومايسين، التداخلات الدوائية)

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (نشرة بريميدون، التحذيرات)

Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (نشرة فيتوميناديون (فيتامين ك1)، التحذيرات والاحتياطات)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (نشرة ميثيل إرغونوفين، التحذيرات)